BPS Bioscience Inc.
San Diego, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 6405 Mira Mesa Blvd #100, San Diego, CA 92121, USA
- Website
- bpsbioscience.com
- Founded
- 2005
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $11,340 |
| FY2024 | $0 |
| FY2023 | $14,897 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
BPS Bioscience Inc. is a for-profit bioscience company headquartered in San Diego, California, that specializes in the manufacture and supply of high-quality enzymes and biological assay reagents to support research and drug discovery initiatives across the federal government. The company has been registered with the System for Award Management (SAM.gov) since May 2009 and maintains expertise in providing recombinant kinases and assay kits that facilitate translational science research. BPS Bioscience's federal contracting experience demonstrates a consistent focus on supplying specialized biochemical products and services that enable the National Institutes of Health and its component agencies to advance critical research missions.
BPS Bioscience Inc.'s federal contract portfolio reflects a strategic concentration on providing biochemical screening services and biological reagent products to the National Center for Advancing Translational Sciences (NCATS) and the National Cancer Institute (NCI). The company's most recent award, dated September 16, 2025, is a $11,340 purchase order from NCATS for a biochemical IC50 screening study involving inhibitory concentration testing on twelve compounds against three protein kinase targets (PKM2, PKL, and PKR), with completion scheduled for September 15, 2026. Prior awards include a $14,897 purchase order from NCI dated March 28, 2023, for biologicals and reagents, and two significant COVID-19 related procurements from NCATS: a $24,586 purchase order awarded August 25, 2022, for an RDRP enzymatic inhibitor screening assay kit, and a $24,167.25 purchase order awarded September 6, 2022, for recombinant PLPRO enzyme purchase. All identified awards have been issued as purchase orders without set-aside designations, and BPS Bioscience has performed as a prime contractor on these awards, with work being conducted at its San Diego facility. The company's contract history demonstrates its established role in supporting drug discovery and translational research across multiple NIH institutes and centers.
SBA capabilities narrative
Screening and profiling for Biotech, R&D, etc.
Wide array of products.
Quick answers
Is BPS Bioscience Inc. registered in SAM.gov?
Yes. BPS Bioscience Inc.'s SAM.gov registration is active through January 12, 2027.
What is BPS Bioscience Inc.'s CAGE code?
BPS Bioscience Inc.'s CAGE code is 5H5U9, and its Unique Entity ID (UEI) is ZLDNP9C134F3.
How much has BPS Bioscience Inc. received in federal contracts?
Federal contracts obligated $11,340 to BPS Bioscience Inc. in fiscal year 2025 and $26,237 in fiscal years 2023 through 2027.
What is BPS Bioscience Inc.'s most recent federal award?
BPS Bioscience Inc.'s most recent federal contract award is Biochemical IC50 screen 12 compounds and 1 control for PKM2, PKL and PKR (75N95C25P00097), from National Center for Advancing Translational Sciences (NIH), on September 16, 2025.
On GovTribe
See BPS Bioscience Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors